We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-12.31%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.52B
AUM Growth
-$397M
Cap. Flow
-$26.5M
Cap. Flow %
-1.74%
Top 10 Hldgs %
80.05%
Holding
36
New
2
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CSBR icon
Champions Oncology
CSBR
+$10.2M
2
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.77M
3
AKTX
Akari Therapeutics
AKTX
+$402K

Top Sells

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$37.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$1.22M

Sector Composition

Rank Sector Weight
1 Healthcare 72.83%
2 Communication Services 10.44%
3 Technology 8.46%
4 Consumer Discretionary 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$355M 23.39%
8,854,255
– –
ARDX icon
2
Ardelyx
ARDX
$1.25B
$178M 11.72%
10,294,096
– –
GRPN icon
3
Groupon
GRPN
$1.07B
$144M 9.49%
2,208,648
– –
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.71B
$107M 7.06%
7,641,250
– –
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$105M 6.91%
1,139,890
– –
DERM
6
DELISTED
Dermira, Inc.
DERM
$81.8M 5.39%
3,506,649
– –
OPWR
7
DELISTED
OPOWER INC COM STK (DE)
OPWR
$80.2M 5.28%
8,997,290
– –
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$66.2M 4.36%
5,149,740
– –
TRVN
9
DELISTED
Trevena, Inc.
TRVN
$49.8M 3.28%
7,699
– –
CBIO
10
Crescent Biopharma
CBIO
$565M
$48M 3.16%
85,751
– –
NVRO
11
DELISTED
NEVRO CORP.
NVRO
$46.1M 3.04%
993,428
– –
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$31.3M 2.06%
1,792,207
– –
HIVE
13
DELISTED
Aerohive Networks
HIVE
$28M 1.84%
4,681,455
– –
LXRX icon
14
Lexicon Pharmaceuticals
LXRX
$1.03B
$25.6M 1.69%
2,382,286
– –
TRIV
15
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$19.7M 1.3%
3,945,191
– –
TCON
16
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$18.5M 1.22%
9,448
– –
CRCM
17
DELISTED
CARE.COM, INC.
CRCM
$16.8M 1.1%
3,260,989
– –
MM
18
DELISTED
MILLENNIAL MEDIA INC COM STK (DE)
MM
$14.4M 0.95%
8,224,752
– –
EXEL icon
19
Exelixis
EXEL
$14B
$12.4M 0.82%
2,207,000
– –
ZSAN
20
DELISTED
Zosano Pharma Corporation
ZSAN
$8.55M 0.56%
3,084
– –
CSBR icon
21
Champions Oncology
CSBR
$75.9M
$8.36M 0.55%
+1,562,500
New +$10.2M
CVT
22
DELISTED
CVENT, INC.
CVT
$8.22M 0.54%
244,106
– –
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$713M
$8.01M 0.53%
324,315
– –
OREX
24
DELISTED
Orexigen Therapeutics, Inc.
OREX
$7.83M 0.52%
370,900
– –
ORKA
25
Oruka Therapeutics
ORKA
$5.17B
$7.24M 0.48%
6,760
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q3 2015 Portfolio in Review

As of Q3 2015, NEA Management Company held 36 positions worth $1.52B, down 21% from $1.91B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

NEA Management Company's Q3 2015 filing shows 2 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was Champions Oncology: 1,562,500 shares worth $8.36M. The largest sale was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 72% a quarter earlier, followed by Communication Services and Technology.

  • NEA Management Company's largest Q3 2015 buy was Champions Oncology: 1,562,500 shares worth $8.36M.
  • NEA Management Company added most to Viracta Therapeutics, Inc. Common Stock in Q3 2015, an estimated $1.77M increase.
  • NEA Management Company's biggest Q3 2015 reduction was Paratek Pharmaceuticals, Inc., cutting an estimated $1.22M.
  • NEA Management Company fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2015, selling an estimated $37.6M.
  • NEA Management Company's ten largest holdings make up 80% of its $1.52B portfolio in Q3 2015.
  • NEA Management Company opened 2 new positions and closed 1 in Q3 2015.
  • NEA Management Company's portfolio value fell 21% quarter-over-quarter to $1.52B.

Based on NEA Management Company's 13F filing for Q3 2015, filed 10 Nov 2015.